Keisuke Hamasaki

Long-Acting Human Serum Albumin-Thioredoxin Fusion Protein Suppresses Bleomycin-Induced Pulmonary Fibrosis Progression

M. Otagiri, T. Maruyama, Hiroshi Watanabe, 2013, The Journal of Pharmacology and Experimental Therapeutics.

Cell-penetrating mechanism of intracellular targeting albumin: Contribution of macropinocytosis induction and endosomal escape.

S. Futaki, T. Ishida, Taro Shimizu, 2019, Journal of controlled release : official journal of the Controlled Release Society.

Cell-penetrating albumin enhances the sublingual delivery of antigens through macropinocytosis.

Panayiotis D. Megaloikonomos, M. Otagiri, Hiroshi Watanabe, 2022, International journal of biological macromolecules.

A human serum albumin-thioredoxin fusion protein prevents experimental contrast-induced nephropathy.

M. Otagiri, T. Maruyama, Hiroshi Watanabe, 2013, Kidney international.

Design and tuning of a cell‐penetrating albumin derivative as a versatile nanovehicle for intracellular drug delivery

S. Futaki, H. Morioka, M. Otagiri, 2018, Journal of controlled release : official journal of the Controlled Release Society.

Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actions

Tomoaki Koga, T. Ishida, M. Otagiri, 2018, Drug delivery.

Mouse Type-I Interferon-Mannosylated Albumin Fusion Protein for the Treatment of Chronic Hepatitis

Hiroshi Watanabe, Taisei Nagasaki, Hitoshi Maeda, 2024, Pharmaceuticals.